Mydecine Innovations Group (OTCMKTS:MYCOF) has announced the engagement of ethica CRO as its contract research organization for its Phase 2a PTSD clinical studies. Ethica CRO is a full-service CRO that conducts and also managed ethical clinical studies on drugs, medical devices, and biologics.
Ethica CRO to lead the clinical trials
The organization offers drug development services to companies that include a range of clinical study biometrics and management services for clinical study phases. Founded in 2002, ethica CRO has demonstrated its commitment to bringing a new ethical dimension to the clinical research space focused on the integration of research participants as research partners instead of treating them as subjects. In 2006, ethica CRO became the first CRO in the globe to be certified for its human research protection program and currently, it is the only CRO globally to have achieved accreditation from different accrediting bodies.
Josh Bartch, Mydecine CEO said that they are delighted to partner with ethica CRO which is renowned for its extensive experience in clinical studies management to the highest ethical and clinical practice standards. He added that engaging ethica CRO for the Phase 2a PTSD clinical studies is among the company’s main goals in the preparation to evaluate how the brain responds to psychedelics and come up with a better understanding of biological underpinnings that result from psychedelics.
Phase 2a PTSD trials to guide the development of psychedelic-assisted therapies
Bartch said that ethica CRO’s experience and insight in such trials offer the best chance to advance Mydecine’s clinical program He asserted that through the clinical preparations they have made and ethica CRO’s experiences the company is positioned for the upcoming phase 2A PTSD studies on Veterans in the US and Canada.
The phase 2a clinical studies will focus on psilocybin-assisted psychotherapy in treating severe PTSD in EMS personnel and Veterans. Mydecine expects to establish the efficacy and safety of psychedelic administered therapy through the trials in a supervised setting. ethica managing director, Murray Jansen said that psychedelics and psychedelic-assisted therapies are becoming an exciting development in the treatment of mental health.